Safety and Efficacy Study of AT-101 in Combination With Docetaxel and Prednisone in Men With HRPC
Public ClinicalTrials.gov record NCT00286793. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-label, Multicenter, Phase I/II Study of AT-101 in Combination With Docetaxel and Prednisone in Men With Hormone Refractory Prostate Cancer (HRPC)
Study identification
- NCT ID
- NCT00286793
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- Ascenta Therapeutics
- Industry
- Enrollment
- 76 participants
Conditions and interventions
Conditions
Interventions
- AT-101 Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Male
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 31, 2006
- Primary completion
- Oct 31, 2009
- Completion
- Oct 31, 2009
- Last update posted
- Jun 28, 2011
2006 – 2009
United States locations
- U.S. sites
- 13
- U.S. states
- 11
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Hot Springs | Arkansas | — | — |
| Not listed | Fort Meyers | Florida | — | — |
| Not listed | Chicago | Illinois | — | — |
| Not listed | Fridley | Minnesota | — | — |
| Not listed | Albuquerque | New Mexico | — | — |
| Not listed | Syracuse | New York | — | — |
| Not listed | Wilmington | North Carolina | — | — |
| Not listed | Portland | Oregon | — | — |
| Not listed | Hilton Head Island | South Carolina | — | — |
| Not listed | Germantown | Tennessee | — | — |
| Not listed | Memphis | Tennessee | — | — |
| Not listed | Nashville | Tennessee | — | — |
| Not listed | Richardson | Texas | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00286793, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 28, 2011 · Synced Jul 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00286793 live on ClinicalTrials.gov.